OnKure Therapeutics reports beneficial ownership disclosures by ADAR1-related holders. ADAR1 Capital Management, LLC is reported to beneficially own 1,014,158 shares of Class A common stock, representing 7.9% of the class, based on 12,861,672 shares outstanding as of November 5, 2025. The holdings include 793,602 shares held by ADAR1 Partners, LP, 119,064 shares held by Spearhead Insurance Solutions IDF, LLC and 101,492 shares held by separately managed accounts, all reported as of December 31, 2025.
ADAR1 Capital Management GP, LLC is shown with 793,602 shares (6.2%) and Daniel Schneeberger is reported to indirectly beneficially own 1,014,158 shares (7.9%) through his managerial roles. The filing is a joint Schedule 13G with a joint filing agreement and signatures dated 02/17/2026.
Positive
None.
Negative
None.
Insights
Large passive stake disclosed: ADAR1-linked entities hold 7.9% of OnKure.
The filing shows ADAR1 Capital Management, LLC with 1,014,158 shares constituting 7.9% of Class A common stock, using the issuer's outstanding share figure of 12,861,672 as of November 5, 2025. The position is aggregated across ADAR1 Partners, Spearhead Insurance Solutions IDF, LLC and separately managed accounts as of December 31, 2025.
Holder decisions will determine any market activity; the filing identifies indirect ownership and managerial relationships but does not state any planned transactions or voting intentions.
Control-person disclosure clarifies attribution through advisory and GP roles.
The schedule clarifies that ADAR1 Capital Management GP, LLC is the general partner of ADAR1 Partners, LP and that Mr. Daniel Schneeberger may be deemed an indirect beneficial owner by virtue of his managerial roles. The filing cites shared voting and dispositive power for the aggregated 1,014,158-share position.
Signatures dated 02/17/2026 and the Joint Filing Agreement are included; timing of any future disclosures would appear in subsequent SEC filings if transactions occur.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
OnKure Therapeutics, Inc.
(Name of Issuer)
Class A Common Stock, par value $0.0001 per share
(Title of Class of Securities)
68277Q105
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
68277Q105
1
Names of Reporting Persons
ADAR1 Capital Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,014,158.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,014,158.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,014,158.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.9 %
12
Type of Reporting Person (See Instructions)
IA, OO
Comment for Type of Reporting Person: Includes (i) 793,602 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 119,064 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 101,492 shares of Common Stock held by other separately managed accounts as of December 31, 2025. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts.
Based on 12,861,672 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of November 5, 2025, reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025.
SCHEDULE 13G
CUSIP No.
68277Q105
1
Names of Reporting Persons
ADAR1 Capital Management GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
793,602.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
793,602.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
793,602.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.2 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: Includes 793,602 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP as of December 31, 2025. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP.
Based on 12,861,672 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of November 5, 2025, reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025.
SCHEDULE 13G
CUSIP No.
68277Q105
1
Names of Reporting Persons
Daniel Schneeberger
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,014,158.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,014,158.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,014,158.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: Includes (i) 793,602 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 119,064 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 101,492 shares of Common Stock held by other separately managed accounts as of December 31, 2025. As the manager of ADAR1 Capital Management, LLC, and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above.
Based on 12,861,672 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of November 5, 2025, reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
OnKure Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
6707 Winchester Circle, Suite 400, Boulder, CO 80301
Item 2.
(a)
Name of person filing:
This Schedule is being filed on behalf of each of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"):
(i) ADAR1 Capital Management, LLC ("ADAR1 Capital Management");
(ii) ADAR1 Capital Management GP, LLC ("ADAR1 General Partner"); and
(iii) Daniel Schneeberger ("Mr. Schneeberger").
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.
(c)
Citizenship:
(i) ADAR1 Capital Management is a Texas limited liability company;
(ii) ADAR1 General Partner is a Texas limited liability company; and
(iii) Mr. Schneeberger is a citizen of Switzerland.
(d)
Title of class of securities:
Class A Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
68277Q105
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(b)
Percent of class:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Mr. Schneeberger is filing this Schedule 13G as a control person in respect of shares beneficially owned by ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E).
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
